Skye Bioscience Inc.’s Post

A late trading day bullish note from Jefferies on biotech name Ardelyx Inc. ($ARDX) results in Ardelyx shares gaining as much as +7%. The Hammerstone Scrolling News Feed: 02:30:27 pm $ARDX Ardelyx shares have 10%-15% upside on HR-5074 bill passage: Jefferies says in late day note. 02:45:54 pm $ARDX extending gains after JEFF comments, up 3.6% on the day. 03:00:39 pm $ARDX +7% - trading at 7-year highs - more - JEFF reit'd their Buy rating and $11 PT earlier - says that Congress has moved HR-5074 into the "markup phase," meaning the bill has increased odds of passing. If HR-5074 passes, a short-term overhang on Ardelyx's Xphozah will be removed, assuring Xphozah's rev growth into 2029 vs. 2027 @ JEFF

Brüush Receives Nasdaq Delisting Notification and Files to Appeal Brueush is appealing a NASDAQ delisting notification. Stay tuned to upcoming updates and contribute to a company that always pushes boundaries. #Brueush #NASDAQ #Delisting #MarketChallenge #FinanceNews #BusinessGrowth #pharma #biotech #pharmiwebcom

In a remarkable turn of events post-Easter, #MesoblastLtd saw its shares soar by an astonishing 60%, pointing to a robust investor confidence in response to recent favorable #USFDA announcements regarding its drug, remestemcel-L. 🚀💼 Highlights include a notable intraday peak just two hours after trading resumed, an increase in substantial holding by an influential US investor, and the market's assertive reaction, dictating promising signs for Mesoblast’s future endeavors. As the biotech firm anticipates to refile its Biologics License Application for remestemcel-L, the industry eyes are firmly on how these developments could further shape Mesoblast's journey through the regulatory process. 💡 Stay tuned for more updates and insights into this evolving story. #Biotech #StockMarket #Investing #MesoblastStock Learn more about the surge and the possible implications for investors: https://lnkd.in/gcD_nc2c

BioNexus (NASDAQ: BGLC) Stock Surges Amidst Mystery Activity https://lnkd.in/dq2Pwyqj #bionexus #NASDAQ #stockmarketnews #BusinessNews #news #NewsAlert

Back to Markets today. Just not like USA Markets over this side though. Pharma research business RedX has told the stock market this morning (2 April 2024) that it is latest capital hungry business to quit the market, in order to make quicker decisions, raise private funds and save costs. Last week Byotrol and Manchester-based drug discovery business C4X made similar announcements citing the cost of a stock market listing and the lack of liquidity in their ailing shares. In a detailed statement to the stock market this morning outlined a timetable that subject to shareholder approval will see RedX become a private company by the last day of April 2024 if a 75% of shareholders vote to delist on 19 April. The poor liquidity has had a “significant impact” on the market valuation of the business, which in turn has had a materially adverse impact on RedX’s ability to seek financing.

In the dynamic world of biotech investments, Mesoblast Ltd's stock has encountered a swift reversal, dropping by 10% today after an impressive previous surge of 71%. 📉🧫 Despite today's downturn, the tide may turn for Mesoblast Ltd in the face of their planned Biologics License Application refiling next quarter and the recent positive FDA engagement. 💡 Investor Insights: - Mesoblast's stock saw substantial growth, outpacing the S&P/ASX 300 Index. - Today's decline may represent a strategic profit-taking step by investors following the stock's leap. - Looking forward, the company anticipates a strong stance in its FDA application prospects. For long-term investors, today's market reaction might offer a vantage point for strategic decision-making. Keep a close watch on Mesoblast Ltd in the upcoming quarter! 🚀💼 Read the full analysis of the Mesoblast stock's recent performance and what it signals to investors: https://lnkd.in/eQiRDpSP #Mesoblast #Biotech #StockMarket #Investment #FDA #BiologicsLicense #MarketAnalysis #Finance

In the face of a #StockMarket downturn, a few companies have managed to swim against the current with their share prices on the rise. #DecmilGroup accepted a lucrative takeover offer, causing its shares to jump by 66%. Southern Cross Electrical Engineer Ltd secured major contract extensions, leading to a 6% increase in share price, while Spartan Resources' new gold discovery and Telix Pharmaceuticals' FDA Fast Track designation for its glioma imaging product sparked positive investor sentiment. It's a testament to their growth potential and strategic moves within the #ASX landscape. 📈🚀 Exploring the resilience and capacity these companies have to deliver positive news, despite broader market selloffs, adds a layer of nuance to our understanding of market dynamics. What can investors learn from these outliers? Read more about what's driving their growth: https://lnkd.in/g8XyhqZH #Investing #Finance #MarketTrends #BusinessGrowth

Explore the dynamics of the Canadian stock market with our latest analysis, featuring the day's top 5 gainers and losers. From ZTEST Electronics' impressive 57% surge to ME Therapeutics' 25% decline, we provide a detailed look at the companies making significant moves in the market. Whether it's innovative discoveries in uranium exploration or advancements in plant-based wellness, our summary offers valuable insights into the factors driving these stocks. Join us for an in-depth review of market trends and potential investment opportunities. #StockMarketAnalysis #CanadianEquities #InvestmentOpportunities https://bit.ly/3uPVgW7

Music to an investor’s ears! 🎻 🎶 Biotech company Illumina (ILMN) is being forced to divest from its cancer-testing subsidiary, Grail. ILMN is part of the S&P 500 index. Grail will be too small for the index when it spins off, and all index-tracking funds will be forced to sell the stock! This forced sale has NOTHING to do with the fundamentals of Grail and everything to do with the restrictive mandates of institutional funds. This could present a fantastic opportunity for individual investors and highlights one of the HUGE advantages we have over institutions. I’ll certainly do more research into this! Any of you interested in buying Grail shares? Quote below is from FT article: https://lnkd.in/dZYd3kza #InvestmentOpportunities #IndividualInvestors #GrailSpinoff

Great couple of days with a world class best of class CFO, Daron Evans of Rezolute Inc. (Nasdaq RZLT) Daron is working hard and investing his capital in this company. He is also becoming part of the executive team. I am excited to see what develops with these drugs in the next several quarters......love it #linkedin #raredisease #rarediseases #biotech #stocks #digitalamarketing